000305555 001__ 305555
000305555 005__ 20251030115607.0
000305555 0247_ $$2doi$$a10.1055/a-2502-1305
000305555 0247_ $$2pmid$$apmid:41151612
000305555 0247_ $$2ISSN$$a0012-0472
000305555 0247_ $$2ISSN$$a1437-5982
000305555 0247_ $$2ISSN$$a1439-4413
000305555 037__ $$aDKFZ-2025-02225
000305555 041__ $$aGerman
000305555 082__ $$a610
000305555 1001_ $$0P:(DE-HGF)0$$aKobold, Sebastian$$b0
000305555 245__ $$aCurrent progress and latest therapeutic options in immuno-oncology.[Aktuelle Fortschritte und neue Therapieoptionen in der Immunonkologie.]
000305555 260__ $$aStuttgart$$bThieme$$c2025
000305555 3367_ $$2DRIVER$$aarticle
000305555 3367_ $$2DataCite$$aOutput Types/Journal article
000305555 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1761746194_3909804$$xReview Article
000305555 3367_ $$2BibTeX$$aARTICLE
000305555 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000305555 3367_ $$00$$2EndNote$$aJournal Article
000305555 520__ $$aRecently approved immunotherapeutic agents in Europe mostly consist of monoclonal antibody-based products. For solid cancers, these comprise the antibody-drug-conjugate Mirvetuximab Soravtansine for platinum-resistant ovarian cancer, the monoclonal antibody Zolbetuximab for Claudin-18.2 positive gastric adenocarcinoma and the checkpoint inhibitor Tislelizumab for esophageal squamous cell carcinoma. For the treatment of relapsed or refractory hematologic B cell malignancies, the use of bispecific T cell engaging antibodies like the BCMA-CD3 targeting Teclistamab and CD20-CD3 targeting Glofitamab were approved by the EMA recently.Combinatorial approaches of conventional chemotherapy and checkpoint inhibitors for the treatment of cholangiocarcinoma, urothelial carcinoma and endometrial carcinoma received recent approval.A CD38 antibody-based bridging therapy for the treatment of newly diagnosed multiple myeloma and the Glofitamab-based approach in combination with Gemcitabine and Oxaliplatin for relapsed DLBCL are the latest additions for hematologic malignancies after promising clinical trials.The first T cell products for the treatment of solid cancers using either tumor-infiltrating lymphocytes or TCR-engineered peripheral blood T cells were approved by the FDA in 2024, for the treatment of advanced melanoma (Lifileucel) and synovial sarcoma (Afamitresgene autoleucel). To further expand the success of T cell products to solid tumors, promising preclinical studies suggest solutions to main obstacles, such as modular CAR T cells, targeting of two antigens simultaneously or generation of cytokine-secreting 4th generation CAR T cells.
000305555 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000305555 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000305555 650_7 $$2NLM Chemicals$$aAntibodies, Monoclonal
000305555 650_2 $$2MeSH$$aHumans
000305555 650_2 $$2MeSH$$aNeoplasms: therapy
000305555 650_2 $$2MeSH$$aNeoplasms: immunology
000305555 650_2 $$2MeSH$$aImmunotherapy: methods
000305555 650_2 $$2MeSH$$aImmunotherapy: trends
000305555 650_2 $$2MeSH$$aAntibodies, Monoclonal: therapeutic use
000305555 650_2 $$2MeSH$$aMedical Oncology: trends
000305555 7001_ $$aMüller, Rasmus$$b1
000305555 773__ $$0PERI:(DE-600)2035474-5$$a10.1055/a-2502-1305$$gVol. 150, no. 22, p. 1335 - 1340$$n22$$p1335 - 1340$$tDeutsche medizinische Wochenschrift$$v150$$x0012-0472$$y2025
000305555 909CO $$ooai:inrepo02.dkfz.de:305555$$pVDB
000305555 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000305555 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000305555 9141_ $$y2025
000305555 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-31$$wger
000305555 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bDEUT MED WOCHENSCHR : 2022$$d2024-12-31
000305555 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-31
000305555 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-31
000305555 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-31
000305555 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-31
000305555 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-31
000305555 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-31
000305555 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-31
000305555 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-31
000305555 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-31
000305555 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-31
000305555 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-31
000305555 9201_ $$0I:(DE-He78)MU01-20160331$$kMU01$$lDKTK Koordinierungsstelle München$$x0
000305555 980__ $$ajournal
000305555 980__ $$aVDB
000305555 980__ $$aI:(DE-He78)MU01-20160331
000305555 980__ $$aUNRESTRICTED